{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344978","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2026-08-11T21:05:23+00:00","discovered_at":"2026-08-11T21:06:00.494485+00:00","generated_at":"2026-08-11T21:06:09.920117+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aardvark reports Q2 net loss $14.4M; ARD-101 clinical hold, HERO/OLE terminated","bullets":["Cash $73.9M as of Jun 30, 2026 vs $91.2M at Mar 31; funds operations into late 2027.","Q2 R&D $10.5M vs $13.1M YoY; G&A $4.6M vs $2.7M; net loss $14.4M both periods.","FDA full clinical hold on ARD-101 IND in May 2026; HERO and OLE trials terminated June 2026.","Assessing unblinded HERO and OLE data in Q3 2026 to determine next steps for ARD-101.","Active FDA discussions to resolve clinical hold; workforce reduction in June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344978","json":"https://secwatch.observer/filing/0001193125-26-344978.json","markdown":"https://secwatch.observer/filing/0001193125-26-344978.md","text":"https://secwatch.observer/filing/0001193125-26-344978.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526344978/0001193125-26-344978-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526344978/ck0001774857-20260811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T21:06:09.920117+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}